What do systematic reviews say?

Serious adverse events at 6 or 12 months · adults and children with strabismus

Serious adverse events and complications · people with liver metastases

Serious adverse events or adverse events · people with asthma

Serious adverse events (number of people) · people with liver cirrhosis and ascites

Serious adverse events (number of events) · people with primary biliary cholangitis

Serious adverse events (number of events) · people with primary biliary cholangitis

Serious adverse events (number of events) · people with primary biliary cholangitis

Serious adverse events (number of events) · people with primary biliary cholangitis

Serious adverse events (number of events) · people with primary biliary cholangitis

Serious adverse events (number of events) · people with primary biliary cholangitis

Serious adverse events (number of events) · people with primary biliary cholangitis

Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

Serious adverse events (number of events) · people with early‐ or very early‐stage hepatocellular carcinoma ineligible for surgery

Serious adverse events (including mortality) · adults with asthma

Pneumonia and other serious adverse events · patients with chronic obstructive pulmonary disease

Non‐serious adverse events for all placebos · patients with mental health disorders

Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)

Serious adverse events: cardiovascular events · Dialysis vascular access outcomes in AVF patients with ESKD

Number of participants experiencing any serious adverse events · Children with obstructive sleep apnoea (aged 15 years or younger)

Serious adverse events at 'less than 3 months' · patients with suspected or diagnosed myocardial infarction